Tarsus Pharmaceuticals (TARS) Net Equity Issued and Repurchased (2020 - 2025)

Tarsus Pharmaceuticals' Net Equity Issued and Repurchased history runs 5 years deep, the most recent figure standing at -$354000.0 for Q2 2025.

• On a quarterly basis, Net Equity Issued and Repurchased fell 29.2% year-over-year to -$354000.0 in Q2 2025; TTM through Mar 2026 was -$354000.0, a 100.97% decrease from a year earlier, with the FY2025 full-year figure at $134.8 million, changed N/A from the prior year.
• Net Equity Issued and Repurchased eased to -$354000.0 in Q2 2025 per TARS's latest filing, from $135.1 million in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $135.1 million in Q1 2025 and bottomed at -$98.3 million in Q4 2024.
• The 4-year median for Net Equity Issued and Repurchased is -$246000.0 (2022), against an average of $7.9 million.
• Across the five-year window, Net Equity Issued and Repurchased surged 45685.78% in 2023 and tumbled 100.04% in 2024, its largest moves.
• Year by year, Net Equity Issued and Repurchased stood at -$74.4 million in 2022, then declined by 7.78% to -$80.1 million in 2023, then dropped by 22.65% to -$98.3 million in 2024, then jumped by 99.64% to -$354000.0 in 2025.
• Per Business Quant, the three latest TARS Net Equity Issued and Repurchased figures stand at -$354000.0 (Q2 2025), $135.1 million (Q1 2025), and -$98.3 million (Q4 2024).